Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.42 |
| ▸ | HTR2C | P28335 | 3/20 | 0.42 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.42 |
| ▸ | MARK3 | P27448 | 1/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.42 |
| ▸ | SIK1 | P57059 | 1/20 | 0.42 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.42 |
| ▸ | MELK | Q14680 | 1/20 | 0.42 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.42 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.42 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.42 |
| ▸ | MARK1 | Q9P0L2 | 1/20 | 0.42 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | ACP1 | P24666 | 2/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13605424 | 0.87 | TSHR (0.43) | JAK3NUAK1MARK3PRKAA2SIK1 | |
| SCHEMBL27739304 | 0.87 | JAK2 (0.42) | JAK2JAK3MCHR1HTR2CNUAK1 | |
| SCHEMBL1735406 | 0.87 | PTPRC (0.42) | JAK2JAK3BRAFABL1PDGFRB | |
| SCHEMBL27739305 | 0.84 | JAK2 (0.43) | JAK2JAK3MCHR1HTR2CNUAK1 | |
| SCHEMBL1735245 | 0.81 | PTPRC (0.41) | BRAFABL1PDGFRB | |
| SCHEMBL13605354 | 0.80 | BRD4 (0.56) | JAK2JAK3NUAK1MARK3PRKAA2 | |
| SCHEMBL13605332 | 0.80 | BRD4 (0.55) | JAK2JAK3MCHR1BRAFABL1 | |
| SCHEMBL13605423 | 0.79 | ROCK2 (0.43) | — | |
| SCHEMBL14499096 | 0.75 | HDAC3 (0.52) | BRAFABL1BCR | |
| SCHEMBL13605331 | 0.75 | BRD4 (0.49) | JAK2JAK3BRAFSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928236-B1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2011-11-23 | — | — | EP | disclosed |
| US-7638523-B2 | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | IRM LLC (BM) | 2009-12-29 | — | — | US | disclosed |
| US-7638523-B2 | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | IRM LLC (BM) | 2009-12-29 | — | — | US | disclosed |
| US-7638523-B2 | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | IRM LLC (BM) | 2009-12-29 | — | — | US | disclosed |
| US-20090264649-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2009-10-22 | — | — | US | disclosed |
| US-20090264649-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2009-10-22 | — | — | US | disclosed |
| US-20090264649-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2009-10-22 | — | — | US | disclosed |
| US-7592349-B2 | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | IRM LLC (BM) | 2009-09-22 | — | — | US | disclosed |
| US-7592349-B2 | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | IRM LLC (BM) | 2009-09-22 | — | — | US | disclosed |
| US-7592349-B2 | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | IRM LLC (BM) | 2009-09-22 | — | — | US | disclosed |
| US-20080139559-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2008-06-12 | — | — | US | disclosed |
| US-20080139559-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2008-06-12 | — | — | US | disclosed |
| US-20080139559-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2008-06-12 | — | — | US | disclosed |
| US-20080139597-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2008-06-12 | — | — | US | disclosed |
| US-20080139597-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2008-06-12 | — | — | US | disclosed |
| WO-2007038669-A9 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC | 2008-05-29 | — | — | WO | disclosed |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | IRM LLC (BM) | 2007-06-28 | — | — | US | disclosed |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | IRM LLC (BM) | 2007-06-28 | — | — | US | disclosed |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | IRM LLC (BM) | 2007-06-28 | — | — | US | disclosed |
| WO-2007038669-A2 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264649-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | KIT, PRKCH, PRKCE | JAK2 308/4885JAK3 755/4885MCHR1 1115/4885 |
| US-20080139597-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | KIT, PRKCH, PRKCE | JAK2 308/4885JAK3 755/4885MCHR1 1115/4885 |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | KIT, PRKCH, PRKCE | JAK2 308/4885JAK3 755/4885MCHR1 1115/4885 |
| US-20080139559-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | KIT, PRKCH, PRKCE | JAK2 308/4885JAK3 755/4885MCHR1 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.